Roche Removes a Blemish: Drugmaker Drops Its One-Time Acne Blockbuster Accutane
Holding less than 5 percent of isotretinoin market and burdened with the costs of personal injury suits, Roche decides to discontinue its acne drug.
Holding less than 5 percent of isotretinoin market and burdened with the costs of personal injury suits, Roche decides to discontinue its acne drug.